Fengtao Zhang
Shenzhen, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Machine learning outperforms large language models for survival prediction in advanced hepatocellular carcinoma: a multicenter study.
Journal: Scientific reports
Published: March 24, 2026
Efficacy and safety of stereotactic body radiation therapy combined with hepatic arterial infusion chemotherapy for hepatocellular carcinoma with portal vein tumor thrombosis:a multicenter propensity score matching study.
Journal: Frontiers in oncology
Published: December 16, 2025
Hepatic arterial infusion chemotherapy combined with apatinib plus camrelizumab for advanced hepatocellular carcinoma with type Vp4 portal vein tumor thrombosis: a multicenter propensity score-matching analysis.
Journal: Frontiers in immunology
Published: November 08, 2025
Hepatic arterial infusion chemotherapy combined with lenvatinib and toripalimab for large hepatocellular carcinoma (> 10 cm) with major portal vein tumor thrombosis: a multicenter propensity score matching analysis.
Journal: Frontiers in immunology
Published: June 11, 2025
Efficacy and Safety of Transarterial Chemoembolization Combined with Hepatic Arterial Infusion Chemotherapy Plus Lenvatinib for Intermediate-Stage Hepatocellular Carcinoma Beyond Up-To-Seven: A Multicentre, Retrospective Propensity Score Matching Analysis.
Journal: Journal of hepatocellular carcinoma
Published: November 14, 2024
Efficacy and Safety of Hepatic Arterial Infusion Chemotherapy(HAIC) Combined with PD-1 Inhibitors for Advanced Hepatocellular Carcinoma with Macrovascular Invasion: A Multicenter Propensity Score Matching Analysis.
Journal: Journal of hepatocellular carcinoma
Published: July 30, 2024
CT-based radiomics features for the differential diagnosis of nodular goiter and papillary thyroid carcinoma: an analysis employing propensity score matching.
Journal: Frontiers in oncology
Published: July 17, 2024
Hepatic artery infusion chemotherapy combined with camrelizumab plus rivoceranib for hepatocellular carcinoma with portal vein tumor thrombosis: a multicenter propensity score-matching analysis.
Journal: Hepatology international
Published: December 06, 2023
Showing 1-8 of 8
Last Updated: 09/26/2026